Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Arbutus BiopharmaLTS:0SGC 53 Cash Ratio is 27.53 as of Jun. 2026, which is 151% above its 10-year median of 10.96. GuruFocus rates LTS:0SGC with a GF Score™ of 53/100 and a GF Value™ of $35.02. The stock has 3 warning signs investors should review. Among 1,377 Biotechnology companies, Arbutus Biopharma ranks better than 95.93% on this metric.
Arbutus Biopharma has a Cash Ratio of 27.53. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for Arbutus Biopharma's Cash Ratio or its related term are showing as below:
LTS:0SGC'
s Cash Ratio Range Over the Past 10 Years
Min: 4.47 Med: 10.96 Max: 27.53
Current: 27.53
During the past 13 years, Arbutus Biopharma's highest Cash Ratio was 27.53. The lowest was 4.47. And the median was 10.96.
LTS:0SGC's Cash Ratio is ranked better than 95.93% of 1377
companies
in the Biotechnology industry
Industry Median: 2.96
vs LTS:0SGC: 27.53
Arbutus Biopharma (LTS:0SGC) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Arbutus Biopharma Cash Ratio Related Terms
Arbutus Biopharma Cash Ratio Historical Data
* Premium members only.
The historical data trend for Arbutus Biopharma's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0SGC vs TBPH, ANNX, SANA: Cash Ratio Comparison
For the Biotechnology subindustry, Arbutus Biopharma's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Arbutus Biopharma Cash Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Arbutus Biopharma's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Arbutus Biopharma's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Arbutus Biopharma (LTS:0SGC) has a Cash Ratio of 27.53 as of Jun. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Arbutus Biopharma and its competitors. This is 151% above median its historical median of 10.96. Over the past decade, Arbutus Biopharma's Cash Ratio has ranged from 4.47 to 27.53. According to the industry distribution chart, Arbutus Biopharma ranks #56 out of 1377 companies in the Biotechnology industry, placing it in the top 4.1%.
Is Arbutus Biopharma's Cash Ratio too high?
Arbutus Biopharma's current Cash Ratio of 27.53 is 151% above median its 10-year median of 10.96. Over the past 10 years, this metric has ranged from a low of 4.47 to a high of 27.53. The Biotechnology industry median Cash Ratio is 2.96. Arbutus Biopharma's value of 27.53 is 830.1% above this industry median. Based on the distribution chart, Arbutus Biopharma ranks #56 out of 1377 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Arbutus Biopharma has a GF Score™ of 53/100, reflecting its overall financial health beyond just this single metric.
How does Arbutus Biopharma's Cash Ratio compare to TBPH and ANNX?
According to the Biotechnology industry distribution chart, Arbutus Biopharma ranks #56 out of 1377 companies for Cash Ratio. This places Arbutus Biopharma in the top 4% of its industry — outperforming the majority of peers. The industry median Cash Ratio is 2.96. Arbutus Biopharma's value of 27.53 is 830.1% above this benchmark. Historically, Arbutus Biopharma's own Cash Ratio has ranged from 4.47 to 27.53 over the past decade. While the company's 10-year median is 10.96 vs. the industry median of 2.96, Arbutus Biopharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Biotechnology company?
The median Cash Ratio among Biotechnology companies is 2.96, based on 1,377 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Arbutus Biopharma's current Cash Ratio of 27.53 is 830.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Arbutus Biopharma and its competitors. For the Biotechnology industry, the median Cash Ratio is 2.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Arbutus Biopharma's current Cash Ratio is 27.53, which is 151% above median its own 10-year median of 10.96. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arbutus Biopharma stock overvalued right now?
Arbutus Biopharma (LTS:0SGC) has a current Cash Ratio of 27.53. The stock's GF Value™ is $35.02, compared to a current price of $3.32 — trading 90.5% below its estimated fair value. The current Cash Ratio is 27.53, which is 151% above median its 10-year median of 10.96 and 830.1% above the Biotechnology industry median of 2.96. Arbutus Biopharma's overall GF Score™ is 53/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Arbutus Biopharma (LTS:0SGC), the current Cash Ratio is 27.53 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Arbutus Biopharma (LTS:0SGC) Overvalued in 2026?
Based on GuruFocus' analysis, Arbutus Biopharma stock appears to be undervalued.
The current stock price of $3.32 is trading 90.5% below its estimated GF Value™ of $35.02.
Key valuation signals for LTS:0SGC:
Cash Ratio: 27.53 (151% above median its 10-year median of 10.96)
GF Value™: $35.02 vs. price of $3.32 (90.5% below fair value)
Industry Position: 830.1% above the Biotechnology median (#56 of 1377)
No single metric tells the full story. See the LTS:0SGC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.
53GF Score
Get the complete analysis for LTS:0SGC
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0SGC has been successfully added to your 
